

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number
WO 03/018555 A1

(51) International Patent Classification⁷: **C07D 209/24**,
405/06, 319/06, C07F 5/02

KOLLY, Roman [CH/CH]; Baselmattweg 167, CH-4123
Allschwil (CH). **END, Nicole** [CH/CH]; Bienenstrasse 6,
CH-4104 Oberwil (CH).

(21) International Application Number: PCT/EP02/09046

(22) International Filing Date: 13 August 2002 (13.08.2002)

(74) Common Representative: **CIBA SPECIALITY
CHEMICALS HOLDING INC.**; Klybeckstrasse 141,
CH-4057 Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01810817.5 22 August 2001 (22.08.2001) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **CIBA
SPECIALITY CHEMICALS HOLDING INC.**
[CH/CH]; Klybeckstrasse 141, CH-4057 Basel (CH).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WOLLEB, Heinz**
[CH/CH]; Steinenbühlstrasse 173, CH-4232 Fehren (CH).
WOLLEB, Annemarie [CH/CH]; Steinenbühlstrasse 173,
CH-4232 Fehren (CH). **VAN DER SCHAAF, Paul, Adri-
aan** [NL/CH]; Marsstrasse 17, CH-4123 Allschwil (CH).


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,

[Continued on next page]


(54) Title: PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES



(I)



(II)



(III)

(57) Abstract: A process for the preparation of compounds of formula (I) wherein R₁ is unsubstituted or substituted C₁-C₈alkyl, R₂, R₃, R₄ and R₅ are each independently of the others hydrogen, unsubstituted or substituted C₁-C₈alkyl, C₁-C₈ alkoxy, phenoxy or benzyloxy, or halogen, Y₁ and Y₂ are each independently of the other hydrogen or a protecting group, or Y₁ and Y₂ together form a protecting bridge, and X₁ is hydrogen, an organic radical or a cation, in which process a compound of formula (II) wherein R₁ R₂ R₃, R₄ and R₅ are as defined above and Z₁ is a leaving group, is reacted, in the presence of a catalytically effective amount of a palladium catalyst, with a compound of formula (III) wherein R₆ is hydrogen, bromine, chlorine, iodine, -OSO₂CF₃, -COCl, -B(OH)₂ or a mono- or di-ester derived from -B(OH)₂, Y₃ and Y₄ are each a protecting group, or Y₃ and Y₄ together form a protecting bridge, and X₁ is as defined above, to form a compound of formula (IV) and if desired the radicals Y₃ and Y₄ are converted into the radicals Y₁ and Y₂ where Y₁ and Y₂ are hydrogen.



WO 03/018555 A1



TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— with international search report

Process for the preparation of indole derivatives


The present invention relates to a process for the preparation of indole derivatives and to novel intermediates.

Indole derivatives of the following formula (1) are known as pharmaceutical active ingredients (e.g. from US-A-4 739 073) or are important precursors in the preparation thereof. An important indole derivative is fluvastatin, an HMG-CoA reductase inhibitor, that is to say an inhibitor of the biosynthesis of cholesterol, which is used in the treatment of hyperlipoproteinaemia and arteriosclerosis.

Known processes for the preparation of indole compounds of formula (1) do not in all cases meet the requirements in terms of the yield and economic viability of the processes.

The problem underlying the present Application is accordingly to provide a new process for the preparation of indole compounds of formula (1), by means of which those compounds can be obtained in as high a yield as possible combined with good economic viability.

The subject matter of the present invention is accordingly a process for the preparation of compounds of formula




wherein R₁ is unsubstituted or substituted C₁-C₈alkyl,

R₂, R₃, R₄ and R₅ are each independently of the others hydrogen, unsubstituted or substituted C₁-C₈alkyl, C₁-C₈alkoxy, phenoxy or benzyloxy, or halogen,

Y₁ and Y₂ are each independently of the other hydrogen or a protecting group, or Y₁ and Y₂ together form a protecting bridge, and

X₁ is hydrogen, an organic radical or a cation,

in which process a compound of formula




(2),

wherein R_1 , R_2 , R_3 , R_4 and R_5 are as defined above, and

Z_1 is a leaving group,

is reacted, in the presence of a catalytically effective amount of a palladium catalyst, with a compound of formula




(3),

wherein R_6 is hydrogen, bromine, chlorine, iodine, $-\text{OSO}_2\text{CF}_3$, $-\text{COCl}$, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$,

Y_3 and Y_4 are each a protecting group, or Y_3 and Y_4 together form a protecting bridge, and

X_1 is as defined above,

to form a compound of formula



(4),

and if desired the radicals Y_3 and Y_4 are converted into the radicals Y_1 and Y_2 where Y_1 and Y_2 are hydrogen.

As C_1 - C_8 alkyl radicals there come into consideration for R_1 , for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, or straight-chain or branched pentyl, hexyl, heptyl or octyl. C_1 - C_4 Alkyl radicals are preferred. R_1 is preferably propyl, especially isopropyl.

As C_1 - C_8 alkyl radicals there come into consideration for R_2 , R_3 , R_4 and R_5 , for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, or straight-chain or branched pentyl, hexyl, heptyl or octyl. The mentioned alkyl radicals may be unsubstituted or substituted, for

example by halogen, such as fluorine. Preference is given to corresponding C₁-C₄alkyl radicals.

As C₁-C₈alkoxy radicals there come into consideration for R₂, R₃, R₄ and R₅ especially C₁-C₄-alkoxy radicals, for example methoxy or ethoxy.


As halogen there comes into consideration for R₂, R₃, R₄ and R₅, for example, fluorine or chlorine, especially fluorine.

R₂, R₃ and R₅ are preferably hydrogen. R₄ is preferably fluorine, especially fluorine bonded in the 4-position.


As protecting groups for Y₁, Y₂, Y₃ and Y₄ there may be used the groups customary for that purpose. The usual protecting groups are indicated, for example, in Protective Groups in Organic Synthesis, Th. W. Greene and P.G.M. Wuts, John Wiley & Sons, Second Edition, 1991 (especially pages 118 to 142).

Preferred as protecting groups Y₁, Y₂, Y₃ and Y₄ are C₁-C₄alkylcarbonyl or silyl radicals; there also come into consideration protecting bridges wherein Y₁ and Y₂ together or Y₃ and Y₄ together form an unsubstituted or substituted alkylene or silyl radical. Examples of C₁-C₄-alkylcarbonyl radicals that may be mentioned include methyl- and ethyl-carbonyl. As silyl radicals there come into consideration, for example, radicals of formula -SiR₃, wherein the R radicals may have identical or different meanings and are unsubstituted or phenyl-substituted C₁-C₈alkyl, especially C₁-C₄alkyl, or unsubstituted or substituted phenyl and wherein the mentioned phenyl radicals may each be further substituted, for example by C₁-C₄alkyl, halo-substituted C₁-C₄alkyl, C₁-C₄alkoxy, nitro or by halogen. The alkylene radicals and silyl radicals mentioned for the protecting bridges may be substituted, for example, by one or two of the R radicals as defined above.

Especially preferred as protecting bridges are radicals of formulae



and



wherein R_7 and R_8 are each independently of the other hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or phenyl, and

R_9 and R_{10} are each independently of the other unsubstituted or phenyl-substituted C_1 - C_8 alkyl or phenyl,

it being possible for each of the above-mentioned phenyl radicals to be further substituted, for example by C_1 - C_4 alkyl, halo-substituted C_1 - C_4 alkyl, C_1 - C_4 alkoxy, nitro or by halogen. The phenyl radicals are preferably unsubstituted.

R_7 and R_8 are preferably hydrogen, C_1 - C_4 alkyl, benzyl or phenyl, especially C_1 - C_4 alkyl, benzyl or phenyl. R_7 and R_8 are especially preferably methyl, tert-butyl or benzyl.

R_9 and R_{10} are preferably C_1 - C_4 alkyl, benzyl or phenyl, especially C_1 - C_4 alkyl or benzyl.

R_9 and R_{10} are especially preferably methyl, tert-butyl or benzyl.

Preferred protecting bridges are those of formula (5a).

Y_1 and Y_2 are especially preferably each independently of the other hydrogen or together form a radical of formula (5a) or (5b), especially a radical of formula (5a).

More especially Y_1 and Y_2 are hydrogen.

As organic radicals there come into consideration for X_1 , for example, unsubstituted or substituted alkyl, alkenyl, alkynyl or phenyl radicals. Special mention may be made of unsubstituted or substituted C_1 - C_{12} alkyl, C_3 - C_{12} alkenyl, C_3 - C_{12} alkynyl or phenyl radicals. In the case of X_1 preference is given to unsubstituted or substituted alkyl radicals, especially C_1 - C_{12} alkyl radicals and preferably C_1 - C_6 alkyl radicals. An example of substituents of the alkyl radicals that may be mentioned is, for example, phenyl unsubstituted or further substituted in the phenyl ring by C_1 - C_4 alkyl, C_1 - C_4 alkoxy, nitro, halogen or by hydroxy. Examples of X_1 that may be mentioned include methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, allyl, benzyl, nitrobenzyl and hydroxybenzyl. X_1 is especially preferably C_1 - C_4 alkyl, especially butyl and preferably tert-butyl.

When the radical X_1 is a cation, the cation may be, for example, sodium or potassium, especially sodium.


X_1 is preferably hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or a cation. Especially preferably X_1 is a cation, such as sodium or potassium, especially sodium.

Z_1 is preferably bromine, chlorine, iodine, $-\text{OSO}_2\text{CF}_3$, $-\text{COCl}$, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$. Especially preferably Z_1 is bromine, chlorine or iodine, especially bromine, or $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$. Bromine is of particular interest.

As mono- or di-ester derived from $-\text{B}(\text{OH})_2$ there come into consideration for R_6 and Z_1 both cyclic and acyclic esters. Suitable mono- or di-ester derivatives of $-\text{B}(\text{OH})_2$ are, for example, those of formula $-\text{B}(\text{OR}')_2$, where the two R' radicals may have identical or different meanings and are hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or unsubstituted or substituted phenyl, or wherein the two R' radicals together form a C_1 - C_8 alkylene radical. Examples of substituents of the phenyl radical that may be mentioned include C_1 - C_4 alkyl, C_1 - C_4 alkoxy, amino, N-mono- or N,N-di- C_1 - C_4 alkyl, halogen, hydroxy and nitro. The R' radicals are preferably hydrogen or C_1 - C_4 alkyl, preference being given to ethyl and especially methyl. It is also preferred that the two R' radicals together form a C_1 - C_8 alkylene radical, especially a C_4 - C_8 alkylene radical. An example of such an alkylene radical that may be mentioned is the radical of formula $-\text{C}(\text{CH}_3)_2-\text{C}(\text{CH}_3)_2-$.

R_6 is preferably hydrogen, bromine, chlorine or iodine, especially hydrogen or iodine, preferably hydrogen.

As compound of formula (2) there is preferably used a compound of formula



(6),

wherein the meanings and preferred definitions given above for Z_1 apply. Z_1 is especially bromine, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$, preferably bromine.

As compound of formula (3) there is preferably used a compound of formula



wherein the meanings and preferred definitions given above for R_6 , R_7 , R_8 and X_1 apply. R_6 is especially preferably hydrogen, bromine, chlorine or iodine, especially hydrogen. R_7 and R_8 are especially preferably each independently of the other hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or phenyl. It is more especially preferred to use the compound of formula (7) together with a compound of formula (6).

Compounds of formula (2) can be obtained, for example, by halogenating suitable compounds wherein Z_1 is hydrogen. The halogenation can be carried out according to generally customary methods. For bromination, mention may be made, for example, of Houben-Weyl, Methoden der organischen Chemie, volume 5/4, pages 233 ff, Georg Thieme Verlag, Stuttgart, 1960. Suitable for the bromination are, for example, elemental bromine, N-bromosuccinimide, pyridinium bromide perbromide or triphenylphosphine dibromide, in an inert, preferably halogenated, solvent, such as carbon tetrachloride, chloroform, chlorobenzene or dichlorobenzene. The bromination is generally carried out at a temperature of from -5 to 25°C , in the case of N-bromosuccinimide at about from 40 to 85°C . The starting compounds wherein Z_1 is hydrogen are known or can be obtained analogously to known processes, for example the processes indicated in US-A-4 739 073. Compounds of formula (2) wherein Z_1 is $-B(OH)_2$ or a mono- or di-ester derived from $-B(OH)_2$ can be obtained analogously to known processes (e.g. starting from the compound of formula (2) wherein Z_1 is bromine).


Compounds of formula (3) are known (e.g. from US-A-4 808 621) or can be obtained analogously to known processes.

As palladium catalyst there are preferably used olefinic palladium complex compounds.

Examples of such palladium catalysts that may be mentioned include compounds of formula



wherein L is a neutral ligand having electron donor properties, Z is an anionic ligand and D denotes substituents, and p is an integer from zero to five and defines the number of substituents on the allyl group;
and compounds of formula



wherein

R₁₁, R₁₂, R_{11'} and R_{12'} are each independently of the others hydrogen, C₁-C₈alkyl, C₁-C₄-alkoxy, C₅-C₈cycloalkyl, C₁-C₄alkylcarbonyloxy, C₁-C₄alkoxycarbonyl, amino, N-mono- or N,N-di-C₁-C₄alkylamino, phenyl or halogen,

R₁₃, R₁₄, R_{13'} and R_{14'} are each independently of the others C₁-C₈alkyl, C₅-C₈cycloalkyl or unsubstituted or substituted phenyl, and

the phenyl rings A and B are unsubstituted or substituted,

and compounds of formula



wherein

- (i) R₁₅ and R₁₆ together with R₁₇ and R₁₈ and R₁₉ and R₂₀, and together with the atoms to which they are bonded, form an unsubstituted or substituted quinolyne ring system, and R₂₁ and R₂₂ are each independently of the other hydrogen or an organic radical; or
- (ii) R₁₇ and R₁₈ together with R₁₉ and R₂₀ and R₂₁ and R₂₂, and together with the atoms to which they are bonded, form an unsubstituted or substituted naphthylene ring system, and R₁₅ and R₁₆ are each independently of the other hydrogen or an organic radical; or
- (iii) R₁₇ and R₁₈ together with R₁₉ and R₂₀, and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring, and R₁₅, R₁₆, R₂₁ and R₂₂ are each independently of the others hydrogen or an organic radical; or

(iv) R_{19} and R_{20} , together with R_{21} and R_{22} , and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring, and R_{15} , R_{16} , R_{17} and R_{18} are each independently of the others hydrogen or an organic radical; or

(v) R_{15} and R_{16} , together with R_{17} and R_{18} , and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring, and R_{19} and R_{20} , together with R_{21} and R_{22} , and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring; and

L and Z are as defined above;

with the proviso that in cases in which R_{15} and R_{16} do not form an unsubstituted or substituted quinolylene or pyridylene ring system, R_{15} and R_{16} , instead of being hydrogen or an organic radical, can also together form unsubstituted or substituted alkylene, which forms a ring together with the nitrogen atom.

L is a neutral ligand having electron donor properties. Suitable ligands are, for example, phosphine ligands of the tertiary phosphine type.

A suitable tertiary phosphine preferably contains from 3 to 40, especially from 3 to 18, carbon atoms. It preferably corresponds to the formula:



wherein R_{23} , R_{24} and R_{25} are each independently of the others C_1 - C_{20} alkyl, C_3 - C_{12} cycloalkyl, C_2 - C_{11} heterocycloalkyl, C_6 - C_{16} aryl, C_7 - C_{16} aralkyl or C_2 - C_{15} heteroarylalkyl, it being possible for those radicals to be substituted by substituents selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkyl, C_6 - C_{16} aryl, $-\text{NO}_2$, SO_3^- , ammonium and halogen. The radicals R_{23} and R_{24} together can be unsubstituted or C_1 - C_6 alkyl-, C_1 - C_6 haloalkyl-, $-\text{NO}_2$ - or C_1 - C_6 alkoxy-substituted tetra- or penta-methylene, which have been fused to one or two bivalent 1,2-phenylene radicals, R_{25} being as defined above.

R_{23} , R_{24} and R_{25} as C_1 - C_{20} alkyl are, for example, methyl, ethyl, n- or iso-propyl or n-, sec- or tert-butyl or straight-chain or branched pentyl, hexyl, heptyl, octyl, isooctyl, nonyl, tert-nonyl, decyl, undecyl or dodecyl.

R_{23} , R_{24} and R_{25} as C_3 - C_{12} cycloalkyl are, for example, cyclopropyl, dimethylcyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

R_{23} , R_{24} and R_{25} as C_2 - C_{11} heterocycloalkyl preferably contain 4 or 5 carbon atoms and one or two hetero atoms from the group O, S and N. Examples include the substituents derived from oxirane, azirine, 1,2-oxathiolane, pyrazoline, pyrrolidine, piperidine, piperazine, morpholine, tetrahydrofuran and tetrahydrothiophene.

R_{23} , R_{24} and R_{25} as C_6 - C_{16} aryl are, for example, mono-, bi- or tri-cyclic, e.g. phenyl, naphthyl, indenyl, azulenyl or anthryl.

R_{23} , R_{24} and R_{25} as C_2 - C_{15} heteroarylalkyl are preferably such radicals that are, as heteroaryl, monocyclic or fused to a further heterocycle or to an aryl radical, e.g. phenyl, and preferably contain one or two, in the case of nitrogen up to four, hetero atoms from the group O, S and N. Examples of such heteroaryl radicals that may be mentioned include: furan, thiophene, pyrrole, pyridine, bipyridine, picolylimine, γ -pyran, γ -thiopyran, phenanthroline, pyrimidine, bipyrimidine, pyrazine, indole, coumarone, thionaphthene, carbazole, dibenzofuran, dibenzothiophene, pyrazole, imidazole, benzimidazole, oxazole, thiazole, dithiazole, isoxazole, isothiazole, quinoline, isoquinoline, acridine, chromene, phenazine, phenoxazine, phenothiazine, triazine, thianthrene, purine and tetrazole. C_2 - C_{15} Heteroarylalkyl consists preferably of the mentioned heterocycles which substitute, for example, C_1 - C_4 alkyl radicals, depending on the length of the carbon chain where possible in the terminal position but alternatively in the adjacent position (1-position) or in the α -position (2-position).

R_{23} , R_{24} and R_{25} as C_7 - C_{16} aralkyl preferably contain from 7 to 12 carbon atoms, e.g. benzyl, 1- or 2-phenethyl or cinnamyl.

Preference is also given to sterically demanding radicals R_{23} , R_{24} and R_{25} , for example cyclic or branched, especially α,α -dibranched, and more especially α -branched, alkyl groups.

Special preference is given to those compounds (8) or (10) in which R_{23} , R_{24} and R_{25} are methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, 1-, 2- or 3-pentyl, 1-, 2-, 3- or 4-hexyl, cyclopentyl, cyclohexyl, phenyl, naphthyl or benzyl, e.g. $(\text{iso-C}_3\text{H}_7)_3\text{P}$, $(\text{C}_5\text{H}_9)_3\text{P}$, $(\text{C}_6\text{H}_{11})_3\text{P}$ and $(\text{C}_6\text{H}_5)_3\text{P}$.

As organic group there comes into consideration for the substituents of the compound of formula (10), for example, C_1 - C_{20} alkyl, C_3 - C_{12} cycloalkyl, C_6 - C_{16} aryl or C_2 - C_{15} heterocyclyl. As examples of such radicals, reference may be made to the corresponding radicals mentioned

above for R_{23} , R_{24} and R_{25} . Examples of substituents of such radicals that may be mentioned include: C_1 - C_4 alkyl, halo-substituted C_1 - C_4 alkyl, for example trifluoromethyl, C_6 - C_{16} aryl, especially phenyl or naphthyl (C_6 - C_{16} aryl, especially phenyl or naphthyl, being unsubstituted or substituted by halogen, carboxy, C_1 - C_4 alkoxycarbonyl, hydroxy, C_1 - C_4 alkoxy, phenyl- C_1 - C_4 alkoxy, C_1 - C_4 alkanoyloxy, C_1 - C_4 alkanoyl, amino, N- C_1 - C_4 alkylamino, N,N-di- C_1 - C_4 -alkylamino, N-phenyl- C_1 - C_4 alkylamino, N,N-bis(phenyl- C_1 - C_4 alkyl)amino, C_1 - C_4 alkanoyl-amino, halo-substituted C_1 - C_4 alkyl, for example trifluoromethyl, sulfo, cyano and nitro), hydroxy, C_1 - C_4 alkoxy, phenyl- C_1 - C_4 alkoxy, C_1 - C_4 alkanoyloxy, amino, N- C_1 - C_4 alkylamino, N,N-di- C_1 - C_4 alkylamino, N-phenyl- C_1 - C_4 alkylamino, N,N-bis(phenyl- C_1 - C_4 alkyl)amino, C_1 - C_4 alkanoylamino, carbamoyl- C_1 - C_4 alkoxy, N- C_1 - C_4 alkylcarbamoyl- C_1 - C_4 alkoxy or N,N-di- C_1 - C_4 alkylcarbamoyl- C_1 - C_4 alkoxy, amino, mono- or di- C_1 - C_4 alkylamino, halogen, for example fluorine, chlorine or bromine, carboxy, C_1 - C_4 alkoxycarbonyl, phenyl-, naphthyl- or fluorenyl- C_1 - C_4 alkoxycarbonyl, for example benzyloxycarbonyl, C_1 - C_4 alkanoyl, sulfo, C_1 - C_4 -alkanesulfonyl, for example methanesulfonyl ($CH_3-S(O)_2-$), phosphono ($-P(=O)(OH)_2$), hydroxy- C_1 - C_4 alkoxyphosphoryl or di- C_1 - C_4 alkoxyphosphoryl, carbamoyl, mono- or di- C_1 - C_4 alkylcarbamoyl, sulfamoyl, mono- or di- C_1 - C_4 alkylaminosulfonyl, nitro and cyano.

As C_1 - C_{20} alkyl preference is given to C_1 - C_8 alkyl, especially C_1 - C_4 alkyl. As C_3 - C_{12} cycloalkyl preference is given to unsubstituted or C_1 - C_4 alkyl-substituted cyclohexyl, especially unsubstituted cyclohexyl. As C_6 - C_{16} aryl preference is given to phenyl or naphthyl, especially phenyl, it being possible for those radicals to be substituted as indicated above.

As unsubstituted or substituted quinolylene ring system in formula (10) there comes into consideration, for example, a quinolin-1,8-ene ring system, which may be substituted as indicated above for the organic radicals. Preference is given to the corresponding unsubstituted ring systems.

As unsubstituted or substituted pyridylene ring system in formula (10) there comes into consideration, for example, a pyridin-1,2-ylene ring system, which may be substituted as indicated above for the organic radicals. Preference is given to the corresponding unsubstituted ring systems.

As unsubstituted or substituted naphthylene ring system in formula (10) there comes into consideration, for example, a naphthyl-1,8-ene ring system, which may be substituted as

indicated above for the organic radicals. Preference is given to the corresponding unsubstituted ring systems.

As unsubstituted or substituted phenylene in formula (10) there comes into consideration, for example, ortho-phenylene, which may be substituted as indicated above for the organic radicals. Preference is given to the corresponding unsubstituted phenylene.

In cases in which R_{15} and R_{16} do not form an unsubstituted or substituted quinolyne or pyridylene ring system and R_{15} and R_{16} , instead of being hydrogen or an organic radical, can also together form unsubstituted or substituted alkylene, which forms a ring together with the nitrogen atom, the alkylene is preferably C_1 - C_8 alkylene, especially C_3 - C_6 alkylene and preferably pentamethylene (in which case a piperidine ring is formed).

An anionic ligand is, for example, the hydride ion (H^-), or a ligand derived, for example, from inorganic or organic acids by removal of protons, e.g. halides (F^- , Cl^- , Br^- and I^-) or anions of oxyacids or derivatives thereof, for example $SnCl_3^-$, $SnCl_5^-$, BF_4^- , $B(aryl)_4^-$, PF_6^- , SbF_6^- or AsF_6^- .

Anions of oxyacids are, for example, sulfate, phosphate, perchlorate, perbromate, periodate, antimonate, arsenate, nitrate, carbonate, the anion of a C_1 - C_8 carboxylic acid, for example formate, acetate, propionate, butyrate, benzoate, phenylacetate, mono-, di- or tri-chloro- or -fluoro-acetate, sulfonates, for example mesylate, ethanesulfonate, propanesulfonate, n-butanesulfonate, trifluoromethanesulfonate (triflate), unsubstituted or C_1 - C_4 alkyl-, C_1 - C_4 -alkoxy- or halo-substituted, especially fluoro-, chloro- or bromo-substituted, benzene-sulfonate or p-toluenesulfonate, e.g. benzenesulfonate, tosylate, p-methoxy- or p-ethoxy-benzenesulfonate, pentafluorobenzenesulfonate or 2,4,6-triisopropylbenzenesulfonate.

Especially preferred anionic ligands are H^- , F^- , Cl^- , Br^- , BF_4^- , PF_6^- , $SnCl_3^-$, SbF_6^- , AsF_6^- , $CF_3SO_3^-$, $C_6H_5-SO_3^-$, 4-methyl- $C_6H_5-SO_3^-$, 3,5-dimethyl- $C_6H_5-SO_3^-$, 2,4,6-trimethyl- $C_6H_5-SO_3^-$ and 4- CF_3 - $C_6H_5-SO_3^-$, acetate and cyclopentadienyl (Cp^-). Special preference is given to acetate, Cl^- , Br^- or I^- . Acetate is more especially preferred.

Suitable substituents D remain unchanged under the conditions of the coupling reactions. The substituents may be selected as desired. Suitable substituents D are selected from the

group of functional groups or derivatised functional groups consisting of amino, C₁-C₄alkyl-amino, C₁-C₄dialkylamino, hydroxy, oxo, thio, -NO₂, carboxy, carbamoyl, sulfo, sulfamoyl, ammonio, amidino, cyano, formylamino, formamido and halogen or are saturated or unsaturated, aliphatic, cycloaliphatic or heterocycloaliphatic radicals, carbocyclic or heterocyclic aryl radicals, fused carbocyclic, heterocyclic or carbocyclic-heterocyclic radicals, which may in turn be combined as desired with further of those radicals and substituted by the mentioned functional groups or derivatised functional groups.

The mentioned substituents and radicals may also be interrupted by one or more bivalent radicals from the group -O-, -S-, -C(=O)-O-, -O-C(=O)-, -C(=O)-N(C₁-C₄alkyl)-, -N(C₁-C₄alkyl)-C(=O)-, -S(=O)-, -S(=O)₂-, -S(=O)-O-, -S(=O)₂-O-, -O-S(=O)-, -O-S(=O)₂-, -S(=O)-N(C₁-C₄alkyl)-, -S(=O)₂-N(C₁-C₄alkyl)-, -(C₁-C₄alkyl)N-S(=O)-, -(C₁-C₄-alkyl)N-S(=O)₂-, -P(=O)-, -P(=O)-O-, -O-P(=O)- and -O-P(=O)-O-.

As aliphatic radicals there come into consideration for D, for example, the radicals mentioned above for R₁₅, R₁₆ and R₁₇ as C₁-C₂₀alkyl.

As cycloaliphatic radicals there come into consideration for D, for example, the radicals mentioned above for R₁₅, R₁₆ and R₁₇ as C₃-C₁₂cycloalkyl.


As heterocycloaliphatic radicals there come into consideration for D, for example, the radicals mentioned above for R₁₅, R₁₆ and R₁₇ as C₂-C₁₁heterocycloalkyl.

As carbocyclic or heterocyclic aryl radicals there come into consideration for D, for example, the radicals mentioned above for R₁₅, R₁₆ and R₁₇ as C₆-C₁₆aryl, C₇-C₁₆aralkyl and C₂-C₁₅-heteroarylalkyl.


The radicals D are especially preferably hydrogen, C₁-C₄alkyl, halogen or phenyl, which may be substituted as indicated above.

Preferably the index p has the values 0, 1 or 2, especially 0.

Suitable olefinic palladium complex compounds (8) having substituents on the allyl group are illustrated by the following structural formulae:



The substituents of the allyl group may, however, also be bonded with one another to form polynuclear bridged complexes according to the following structure:



Preference is given to olefinic palladium complex compounds (8) without substituents on the allyl group, which is bonded to palladium (index p is zero), and wherein L is the tricyclohexylphosphine or triisopropylcyclophosphine group and X is halogen, for example chlorine, bromine or iodine.

In addition to the compounds of formula (8) there also come into consideration those of formula



wherein the meanings and preferred definitions given above for D, X and p apply. The compounds of formula (8a) are added together with the ligand, the palladium complex being formed *in situ*.

Suitable palladium catalysts of formulae (8) and (8a) are known (e.g. from WO-A-99/47474) or can be obtained analogously to known palladium catalysts.

Examples of substituents of the phenyl rings A and B of the compounds of formula (9) that may be mentioned include C₁-C₄alkyl, C₁-C₄alkoxy, C₅-C₈cycloalkyl, C₁-C₄alkylcarbonyloxy, C₁-C₄alkoxycarbonyl, amino, N-mono- or N,N-di-C₁-C₄alkylamino, phenyl and halogen. As those substituents, preference is given to C₁-C₄alkyl, C₅-C₈cycloalkyl, such as cyclohexyl, or phenyl.


R₁₁, R₁₂, R₁₁' and R₁₂' are preferably each independently of the others hydrogen, C₁-C₄alkyl, C₅-C₈cycloalkyl, such as cyclohexyl, or phenyl.

R₁₃, R₁₄, R₁₃' and R₁₄' are preferably each independently of the others C₁-C₈alkyl, especially C₁-C₄alkyl, C₅-C₈cycloalkyl such as cyclohexyl, or unsubstituted or C₁-C₄alkyl-substituted phenyl.

For X there come into consideration the meanings and preferred definitions given above for the anionic ligand Z.


Palladium catalysts of formula (9) are known (e.g. from EP-A-0 690 046) or can be obtained analogously to known palladium catalysts.

Suitable palladium complex compounds of formula (10) are illustrated by the following structural formula:



wherein the meanings and preferred definitions given above for R_{15} , R_{16} , Z and L apply. In those formulae preferably R_{15} and R_{16} are C_1 - C_4 alkyl, especially methyl, L is $P(phenyl)_3$ or $P(isopropyl)_3$ and Z is OAc .

In addition to the compounds of formula (10) there also come into consideration those of formula




(12)

wherein for the substituents the meanings and preferred definitions given above apply.


The compounds of formula (12) are added together with the ligand, the palladium complex being formed *in situ*.

Special preference is given to suitable compounds of formula



(13).

The compounds of formula (10) can be obtained analogously to known processes. For example, they may be obtained by the reaction of a compound of formula



(14),

wherein the substituents are as defined above,
with a palladium salt of formula



(15),

wherein Z is as defined above, in a suitable solvent, especially a halogenated, preferably chlorinated, hydrocarbon, preference being given to C₁-C₄alkylhalides, such as chloroform or methylene chloride, at a temperature of, for example, from 0 to 50°C, especially from 20 to 30°C, and isolation of the resulting complex (generally, especially in the case when Z is C₁-C₄alkylcarbonyl, a dimeric compound of formula (12) bridged by way of Z is obtained). The resulting compound can then be reacted with a ligand



(16),

wherein the meanings given above apply, optionally directly *in situ* in the reaction mixture used for the catalysis. The reaction is carried out in a suitable solvent, for example an ether, such as tetrahydrofuran, at a temperature of, for example, from 0 to 50°C, especially from 20 to 30°C. The resulting complex can then be used either directly or after isolation.

The starting materials for the preparation of the compound of formula (10) are known or can be obtained analogously to known processes.

As palladium catalysts special preference is given to those of formulae (8), (8a), (10) and (12), especially those of formulae (10) and (12). Those of formula (10) are of particular interest.

The reaction conditions for the coupling reactions of the compounds of formula (2) with those of formula (3) are described in the literature and correspond to the reaction conditions known for so-called Suzuki and Heck coupling reactions.

The process according to the invention can be carried out by using either the compound of formula (2) or the compound of formula (3) as initial charge, or by introducing both compounds.

The term "catalytic amount" preferably means an amount of about from 0.0001 to 15 mol%, especially from 0.01 to 10 mol% and more especially from 0.1 to 10 mol%, based on the amount of substrate used.

The molar ratio of the reaction partners in the coupling reactions of compounds of formula (2) to the compounds of formula (3) is generally in the range from 0.5:1 to 1:10, a ratio in the range from 0.5:1 to 1:5 being preferred. A ratio of from 1:1 to 1:2 is especially preferred. The reaction is carried out at a temperature ranging from with cooling up to the boiling temperature of the solvent, especially from room temperature up to the boiling temperature of the solvent (reflux conditions). Preference is given to temperatures of from 25 to 170°C, especially from 50 to 150°C and preferably from 100 to 150°C. Suitable solvents are customary, especially relatively high-boiling, solvents, for example nonpolar aprotic solvents, e.g. xylene or toluene, or polar aprotic solvents, e.g. dimethylformamide. The obtainable reaction product can be worked up and isolated in a manner known *per se*. Mention may be made of customary purification methods, for example removal of the solvent and optionally subsequent separation processes, e.g. fine distillation, recrystallisation, preparative thin-layer chromatography, column chromatography, preparative gas chromatography etc..


Subsequent to the preparation of the compound of formula (4), the radicals Y_3 and Y_4 can be converted into the radicals Y_1 and Y_2 where Y_1 and Y_2 are hydrogen. That removal of the protecting groups can be carried out in conventional manner, for example by reaction under basic or acidic conditions. Removal of the protecting groups is preferably carried out subsequent to the preparation of the compound of formula (4).

When X_1 is hydrogen or an organic radical, X_1 can be converted into a cation, for example by hydrolysis.

The hydrolysis can be carried out, for example, by conventional basic hydrolysis of the esters. For that purpose, the compound of formula (4) is treated with about one mole of an inorganic base, for example an alkali metal hydroxide, e.g. potassium hydroxide or especially sodium hydroxide, in a mixture of water and a water-miscible organic solvent, for example a lower alcohol or an ether, such as methanol, ethanol or tetrahydrofuran, at a temperature of, for example, from 0 to 80°C. It is also possible to carry out the operation with slightly less than a stoichiometric amount of base and then to remove the excess ester by means of extraction with an organic solvent that is not miscible with water, e.g. tert-butyl methyl ether; freeze-drying can then be carried out. In order to form the free acid, the ester can also be hydrolysed in an acidic medium, it being possible for that hydrolysis to be carried out according to processes known *per se*. Hydrolysis is preferably carried out, preferably using sodium hydroxide, subsequent to the preparation of the compound of formula (4).

In dependence upon the optical purity of the compound of formula (3) used, the compounds of formula (1) can be obtained in the form of racemates or in the form of stereoisomerically pure compounds. Stereoisomerically pure compounds are to be understood here and hereinafter as compounds that are at least 60%, especially 80% and preferably 90%, pure. Such compounds are especially preferably at least 95%, preferably 97.5% and more especially 99% in stereoisomerically pure form.

For example, when corresponding stereoisomerically pure compounds of formula (3) are used, compounds of formula (1) can be obtained in pure form, especially in the (3R,5S) configuration given below:




(1a).

Further stereoisomers that may be mentioned include those of the corresponding (3R,5R), (3S,5S) and (3S,5R) configurations.

When a racemate is used as compound of formula (3), separation of the racemate can also be effected subsequent to the preparation of the compound of formula (1). The racemate can be separated into the optically pure antipodes, for example, by known processes for separating enantiomers, for example by means of preparative chromatography on chiral supports (HPLC) or by esterification and crystallisation with optically pure precipitants, e.g. with D -(-) or L -(-)-mandelic acid or (+)- or (-)-10-camphorsulfonic acid.

The present invention relates also to compounds of formula




(17),

wherein for R' the meanings and preferred definitions given above apply. The two R' radicals preferably have identical or different meanings and are hydrogen, unsubstituted or phenyl-substituted C₁-C₈alkyl or unsubstituted or substituted phenyl, or the two R' radicals together form a C₁-C₈alkylene radical.

As examples of substituents of the phenyl radical there may be mentioned C₁-C₄alkyl, C₁-C₄-alkoxy, amino, N-mono- or N,N-di-C₁-C₄alkyl, halogen, hydroxy and nitro. The R' radicals are preferably hydrogen, benzyl or C₁-C₄alkyl, preference being given to ethyl or especially methyl. It is also preferred that the two R' radicals together form a C₁-C₈alkylene radical, especially a C₄-C₈alkylene radical. As an example of such an alkylene radical there may be mentioned the radical of formula -C(CH₃)₂-C(CH₃)₂-.

The present invention relates also to compounds of formula




(18),

wherein for R_7 , R_8 and X_1 the meanings and preferred definitions given above apply. R_7 and R_8 are especially each independently of the other hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or phenyl, especially C_1 - C_4 alkyl or benzyl, preferably C_1 - C_4 alkyl. X_1 is preferably C_1 - C_4 alkyl.

The following Examples illustrate the invention:

Example 1:


2-Bromo-3-(4-fluoro-phenyl)-1-isopropyl-1H-indole



20 g (78.95 mmol) of 3-(4-fluoro-phenyl)-1-isopropyl-1H-indole, 200 ml of THF and 200 ml of chlorobenzene are introduced into a 1.5 litre sulfonating flask equipped with an anchor stirrer, thermometer and nitrogen supply, and the mixture is cooled to 3°C with stirring. 26.58 g (78.95 mmol) of pyridinium bromide perbromide are then added, and stirring is carried out for 1.25 hours at 3°C. Thereafter, in the course of 10 minutes, 680 g of a 5% sodium hydrogen carbonate solution are added dropwise. The phases are separated and the aqueous phase is extracted three times with 150 ml of chlorobenzene. The combined organic phases are washed twice with 340 ml of 5% sodium hydrogen carbonate solution and twice with 220 ml of water, dried over magnesium sulfate, filtered and concentrated by evaporation. The brown residue is dissolved in 125 ml of methylene chloride; 125 ml of 94% ethanol are added, and the methylene chloride is distilled off at normal pressure. The solution is cooled slowly to room temperature, and then to 3°C, and the precipitate is filtered off, washed three times with 10 ml of ice-cold 94% ethanol and dried overnight at RT/125 T. Beige crystals are obtained having a melting point of from 110 to 111.5°C. Elemental analysis: found 4.95% H; 61.23 % C; 4.04% N; 22.9% Br; 5.67% F. Theory 4.55% H; 61.46% C; 4.22% N; 24.05% Br; 5.72% F.

Example 2:

1-Isopropyl-3-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole



5.5 ml of a 1.6M solution of n-butyllithium in hexane are added, at a temperature of -78°C , to a solution of the above indole bromide (2.65 g) in 60 ml of a mixture of dry tetrahydrofuran/diethyl ether (ratio by volume 1:1). Stirring is carried out at a temperature of -78°C for 15 minutes. A solution of 2-ethoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.4 ml) in diethyl ether (2 ml) is then added. The reaction mixture is heated to room temperature in the course of about 2.5 hours and then diluted with diethyl ether. The organic phase is washed with saturated sodium chloride solution, dried over Na_2SO_4 and is then concentrated by evaporation. The desired product is obtained in the form of yellowish crystals (3.0 g, 100%).
 $^1\text{H-NMR}$ (CDCl_3): 1.27 (s, 12 H); 1.69 (d, $J = 7.0$, 6 H); 5.08-5.20 (m, 1 H); 7.05-7.12 (m, 3 H); 7.21-7.26 (m, 1 H); 7.44-7.49 (m, 2 H); 7.55-7.61 (m, 2 H).

Example 3:

(4R,6S)-3-[6-(2-Iodo-vinyl)-2,2-dimethyl-[1,3]dioxan-4-yl]-acetic acid tert-butyl ester




A solution of the above aldehyde (990 mg) and CHI_3 (2.26 g) in tetrahydrofuran (18 ml) is added at a temperature of 0°C , under argon, to a suspension of dry CrCl_2 (2.83 g) in dry tetrahydrofuran (36 ml). The reaction mixture is stirred at room temperature for 16 hours. The reaction is then stopped by the addition of water and extraction is carried out with diethyl ether. The organic phase is washed with saturated sodium chloride solution and dried over Na_2SO_4 , and the solvent is removed under reduced pressure. The crude product is purified by chromatography (hexane / AcOethyl 1:1). The vinyl iodide (470 mg, 32%) is obtained in the form of a yellow oil (7:3 ratio of E/Z).

$^1\text{H-NMR}$ (CDCl_3): 1.21-1.39 (m, 1H); 1.40 (s, ~3 H); 1.44 (s, 6.3 H); 1.45 (s, ~3 H); 1.46 (s, 2.7 H); 1.53 (s, 0.3 H); 1.56-1.78 (m, 1 H); 2.29 (dd, $J = 15.4, 6.3, 0.7$ H); 2.32 (dd, $J = 15.0, 6.2, 0.3$ H); 2.44 (dd, $J = 15.3, 7.1, 1$ H); 4.21-4.38 (m, ~2 H); 6.23 (dd, $J = 7.3, 7.3, 0.3$ H,

Z); 6.34 (dd, J = 7.9, 0.9, 0.3 H, Z); 6.39 (dd, J = 14.7, 0.9, 0.7 H, E); 6.52 (dd, J = 14.7, 5.6, 0.7 H, E).

Example 4:

[4R,6S]-{6-[2-(1-Isopropyl-3-(4-fluorophenyl)-1H-indol-2-yl)-vinyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-acetic acid tert-butyl ester




Water (6 ml), K_3PO_4 (427 mg) and $Pd(dppf)Cl_2$ (18 mg) [dppf = 1,1'-bis(diphenylphosphino)-ferrocene] are added to a solution of the boronate (303 mg) and vinyl iodide (458 mg) in dimethoxyethane (6 ml). The reaction mixture is stirred under argon at a temperature of 60°C for 40 hours. After cooling to room temperature, the reaction mixture is poured into water and extracted with AcOethyl. The combined organic phases are washed with saturated sodium chloride solution, dried over Na_2SO_4 and concentrated. The crude product is purified by chromatography (hexane / AcOethyl, 5:1). The desired product (235 mg, 46%) is obtained in the form of a yellowish foam (7:3 ratio of E/Z).

1H -NMR ($CDCl_3$): 1.43 (s, 3 H); 1.46 (s, 9 H); 1.51 (s, 3 H); 1.55-1.63 (m, 2 H); 1.67 (d, J = 7.0, 6 H); 2.04 (dd, J = 15.0, 5.0, 0.3 H); 2.20 (dd, J = 15.0, 7.8, 0.3 H); 2.31 (dd, J = 15.4, 6.2, 0.7 H); 2.46 (dd, J = 15.2, 7.0, 0.7 H); 3.78-3.89 (m, 0.3 H); 4.18-4.34 (m, 1 H); 4.43-4.48 (m, 0.7 H); 4.68-4.80 (m, 0.3 H); 4.78-4.90 (m, 0.7 H); 5.67 (dd, J = 16.4, 5.9, 0.7 H); 5.74 (dd, J = 11.4, 8.2, 0.3 H); 6.53 (d, J = 11.1, 0.3 H); 6.62 (d, J = 16.1, 0.7 H); 7.04-7.23 (m, 4 H); 7.37-7.46 (m, 2 H); 7.52-7.56 (m, 1.4 H); 7.67 (d, J = 8.0, 0.6 H).

Examples 5-16:

In the following Examples, reference is made to the following compounds:

a) Starting materials




Compound A1: X = Br

Compound A2: X = B[OC(CH₃)₂C(CH₃)₂O]

Compound B1: R₁ = R₂ = CH₃; R₃ = C(CH₃)₃; Y = H

Compound B2: R₁ = R₂ = CH₃; R₃ = C(CH₃)₃; Y = I

b) Palladium catalysts



Compound C1: R₁ = R₂ = CH₃; X = OAc

Compound D1: R₁ = R₂ = CH₃; X = OAc; L = P(phenyl)₃

Compound E1: X = Br; L = P(isopropyl)₃

Compound F1: dppe = 1,1'-bis(diphenylphosphino)ferrocene (commercially obtainable from Fluka)

General process procedure:

Compound A (1 molar equivalent) and compound B (1.2 molar equivalents, based on compound A) are dissolved in the respective solvent (10% solution) indicated in the following Tables 1(a) to 1(c). The base and the palladium catalyst are also added thereto. The reaction mixture is heated to the temperature shown in the Tables. After the reaction time indicated, the conversion and the yield are determined by means of HPLC. The results and reaction conditions are shown in the following Tables 1(a) to 1(c). The yield is determined by means of HPLC.

Generally used abbreviations:

Ac: acetyl

DMF: dimethylformamide

NMP: N-methylpyrrolidone

DME: dimethoxyethane

Table 1(a)

Example	5	6	7	8
Compound A	A1	A1	A1	A1
Compound B	B1	B1	B1	B1
Palladium catalyst (mol% Pd, based on compound A)	D1 (1)	D1 (1)	D1 (1)	D1 (1)
Base (molar equivalent, based on compound A)	KOAc (1.1)	NaOAc (1.1)	K pivaloate (1.1)	K propionate (1.1)
Solvent	DMF	DMF	DMF	DMF
Reaction temperature	140°C	140°C	140°C	140°C
Reaction time	16 hours	16 hours	16 hours	16 hours
Conversion, based on compound A)	100%	48%	94%	94%
Yield	68%	33%	62%	62%

Table 1(b)


Example	9	10	11	12
Compound A	A1	A1	A1	A1
Compound B	B1	B1	B1	B1
Palladium catalyst (mol% Pd, based on compound A)	C1 (1) + P(n-butyl) ₃ (2)	C1 (1) + P(cyclohexyl) ₃ (2)	C1 (1) + P(isopropyl) ₃ (2)	C1 (1) + P(phenyl) ₃ (2)
Base (molar equivalent, based on compound A)	KOAc (1.1)	KOAc (1.1)	KOAc (1.1)	KOAc (1.1)
Solvent	DMF	DMF	DMF	DMF
Reaction temperature	140°C	140°C	140°C	140°C
Reaction time	3 hours	3 hours	3 hours	3 hours
Conversion, based on compound A)	60%	62%	55%	84%
Yield	47%	48%	38%	46%
Note:	catalyst is prepared <i>in situ</i>	catalyst is prepared <i>in situ</i>	catalyst is prepared <i>in situ</i>	catalyst is prepared <i>in situ</i>

Table 1(c)

Example	13	14	15	16
Compound A	A1	A1	A1	A2
Compound B	B1	B1	B1	B2
Palladium catalyst (mol% Pd, based on compound A)	D1 (1)	D1 (1)	E1 (1)	F1 (2.5)
Base (molar equivalent, based on compound A)	KOAc (1.1)	KOAc (1.1)	KOAc (1.1)	K ₃ PO ₄ (2.5)
Solvent	NMP	NMP	NMP	DME/H ₂ O in a ratio by volume of 1:1
Reaction temperature	140°C	200°C	200°C	60°C
Reaction time	18 hours	1 hour	1 hour	40 hours
Conversion, based on compound A)	94%	96%	96%	98%
Yield	62%	75%	75%	46%

Example 17


Erythro-(±)-E-7-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid tert-butyl ester




In a 5 ml round-bottomed flask, 0.1 g of erythro-(±)-E-(6-{2-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-vinyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester and 8 mg of pyridinium p-toluenesulfonate are dissolved in 1.5 ml of acetonitrile; 0.1 ml of water is added and the clear solution is stirred at room temperature for 24 hours. The reaction mixture is then diluted with ethyl acetate, washed twice with saturated sodium chloride solution, dried over magnesium sulfate and concentrated by evaporation. 0.1 g of a beige solid is obtained, which, according to TLC, HPLC and NMR, corresponds to the product prepared as reference in the form of the tert-butyl ester analogously to US 4 739 073, Example 5.

Example 18


Erythro-(±)-(E)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoate sodium salt



In a 10 ml three-necked round-bottomed flask equipped with a magnetic stirrer, thermometer, septum, syringe and nitrogen supply, 0.49 g of erythro-(±)-(E)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid tert-butyl ester is hydrolysed according to O. Tempkin, Tetrahedron 31, 10659 (1997), there being obtained 0.35 g (77% of the theory) of a pale beige powder, the NMR of which corresponds to that of the commercial product.

Preparation example for palladium catalyst:

0.67 g of N,N-dimethylbenzylamine is slowly added to a solution of 1 g of Pd(OAc)₂ in 30 ml of chloroform. The reaction mixture is stirred for 2 hours and then filtered (silica). The resulting yellow solution is concentrated *in vacuo* and the resulting oil is suspended in a few ml of hexane. The yellow suspension is centrifuged and the resulting yellow powder is dried *in vacuo*. The compound of the symbolic formula



is obtained in quantitative yield. That dimer is dissolved in 10 ml of tetrahydrofuran, and 1 equivalent of triphenylphosphine is added. The reaction mixture is then stirred for 1 hour.

The resulting suspension is concentrated *in vacuo* and the white powder is washed with hexane. The desired product is obtained in a 90% yield in the form of a yellowish powder.


^1H NMR (δ in CDCl_3): 7.75 and 7.35 (2m, 15, PPh_3); 6.93 (d), 6.8 (t), 6.34 (m) (4, aromatic-H); 4.02 (d, 2.05 Hz, 2, CH_2N); 2.79 (d, 2.34 Hz, 6, NMe_2); 1.27 (s, 3, OAc)

^{31}P NMR (δ in CDCl_3): 43

For preparation, see also Ryabov *et al.* in J. Chem. Soc., Perkin Trans. 1983, pages 1503-1508.

What is claimed is:

1. A process for the preparation of a compound of formula



wherein R_1 is unsubstituted or substituted C_1 - C_8 alkyl,

R_2 , R_3 , R_4 and R_5 are each independently of the others hydrogen, unsubstituted or substituted C_1 - C_8 alkyl, C_1 - C_8 alkoxy, phenoxy or benzyloxy, or halogen,

Y_1 and Y_2 are each independently of the other hydrogen or a protecting group, or Y_1 and Y_2 together form a protecting bridge, and

X_1 is hydrogen, an organic radical or a cation,

in which process a compound of formula



wherein R_1 , R_2 , R_3 , R_4 and R_5 are as defined above, and

Z_1 is a leaving group,

is reacted, in the presence of a catalytically effective amount of a palladium catalyst, with a compound of formula




wherein R_6 is hydrogen, bromine, chlorine, iodine, $-\text{OSO}_2\text{CF}_3$, $-\text{COCl}$, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$,

Y_3 and Y_4 are each a protecting group, or Y_3 and Y_4 together form a protecting bridge, and

X_1 is as defined above,

to form a compound of formula



(4),


and if desired the radicals Y_3 and Y_4 are converted into the radicals Y_1 and Y_2 where Y_1 and Y_2 are hydrogen.

2. A process according to claim 1, wherein R_1 is isopropyl.


3. A process according to either claim 1 or claim 2, wherein R_2 , R_3 and R_5 are hydrogen and R_4 is fluorine bonded in the 4-position.

4. A process according to any one of claims 1 to 3, wherein Y_1 and Y_2 are each independently of the other hydrogen, C_1 - C_4 alkylcarbonyl or a silyl radical or Y_1 and Y_2 together form an unsubstituted or substituted alkylene or silyl radical.

5. A process according to any one of claims 1 to 4, wherein Y_1 and Y_2 are each independently of the other hydrogen or together form a radical of formula



or



wherein


R_7 and R_8 are each independently of the other hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or phenyl, and

R_9 and R_{10} are each independently of the other unsubstituted or phenyl-substituted C_1 - C_8 -alkyl or phenyl.

6. A process according to any one of claims 1 to 5, wherein X_1 is hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or a cation.


7. A process according to any one of claims 1 to 6, wherein X_1 is a cation, especially sodium.

8. A process according to any one of claims 1 to 7, wherein R_6 is hydrogen, bromine, chlorine or iodine, especially iodine or hydrogen.
9. A process according to any one of claims 1 to 8, wherein Z_1 is bromine, chlorine, iodine, $-\text{OSO}_2\text{CF}_3$, $-\text{COCl}$, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$, especially bromine, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$.
10. A process according to any one of claims 1 to 8, wherein as compound of formula (2) there is used a compound of formula



(6),


wherein Z_1 is bromine, $-\text{B}(\text{OH})_2$ or a mono- or di-ester derived from $-\text{B}(\text{OH})_2$, and as compound of formula (3) there is used a compound of formula



(7),

wherein R_6 is hydrogen, bromine, chlorine or iodine, especially hydrogen or iodine, X_1 is as defined for claim 1, and R_7 and R_8 are each independently of the other hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or phenyl.


11. A process according to any one of claims 1 to 10, wherein there is used as palladium catalyst a compound of formula



(8),

wherein L is a neutral ligand having electron donor properties, Z is an anionic ligand and D denotes substituents, and p is an integer from zero to five and defines the number of substituents on the allyl group;

or a compound of formula



wherein

R₁₁, R₁₂, R_{11'} and R_{12'} are each independently of the others hydrogen, C₁-C₈alkyl, C₁-C₄-alkoxy, C₅-C₈cycloalkyl, C₁-C₄alkylcarbonyloxy, C₁-C₄alkoxycarbonyl, amino, N-mono- or N,N-di-C₁-C₄alkylamino, phenyl or halogen,

R₁₃, R₁₄, R_{13'} and R_{14'} are each independently of the others C₁-C₈alkyl, C₅-C₈cycloalkyl or unsubstituted or substituted phenyl, and

the phenyl rings A and B are unsubstituted or substituted,

or a compound of formula



wherein

(i) R₁₅ and R₁₆ together with R₁₇ and R₁₈ and R₁₉ and R₂₀, and together with the atoms to which they are bonded, form an unsubstituted or substituted quinolylene ring system, and R₂₁ and R₂₂ are each independently of the other hydrogen or an organic radical; or

(ii) R₁₇ and R₁₈ together with R₁₉ and R₂₀ and R₂₁ and R₂₂, and together with the atoms to which they are bonded, form an unsubstituted or substituted naphthylene ring system, and R₁₅ and R₁₆ are each independently of the other hydrogen or an organic radical; or

(iii) R₁₇ and R₁₈ together with R₁₉ and R₂₀, and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring, and R₁₅, R₁₆, R₂₁ and R₂₂ are each independently of the others hydrogen or an organic radical; or

(iv) R_{19} and R_{20} , together with R_{21} and R_{22} , and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring, and R_{15} , R_{16} , R_{17} and R_{18} are each independently of the others hydrogen or an organic radical; or

(v) R_{15} and R_{16} , together with R_{17} and R_{18} , and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring, and R_{19} and R_{20} , together with R_{21} and R_{22} , and together with the atoms to which they are bonded, form an unsubstituted or substituted phenylene ring; and

L and Z are as defined above;


with the proviso that in cases in which R_{15} and R_{16} do not form an unsubstituted or substituted quinolylene or pyridylene ring system, R_{15} and R_{16} , instead of being hydrogen or an organic radical, can also together form unsubstituted or substituted alkylene, which forms a ring together with the nitrogen atom.

12. A process according to claim 11, wherein there is used as palladium catalyst a compound of formula (8) or (10).

13. A process according to claim 11, wherein there is used as palladium catalyst a compound of formula (10).

14. A process according to any one of claims 1 to 13, wherein, subsequent to the preparation of the compound of formula (4), the radicals Y_3 and Y_4 are converted into the radicals Y_1 and Y_2 where Y_1 and Y_2 are hydrogen, and, when X_1 is hydrogen or an organic radical, X_1 is converted into a cation.

15. A compound of formula




(17),

wherein the two R' radicals have identical or different meanings and are hydrogen, unsubstituted or phenyl-substituted C_1 - C_8 alkyl or unsubstituted or substituted phenyl or wherein the two R' radicals together form a C_1 - C_8 alkylene radical.

16. A compound according to claim 15, wherein the two R' radicals have identical or different meanings and are hydrogen, benzyl or C₁-C₄alkyl, or the two R' radicals together form a C₄-C₈alkylene radical.

17. A compound of formula



(18),

wherein R₇ and R₈ are each independently of the other hydrogen, unsubstituted or phenyl-substituted C₁-C₈alkyl, or phenyl, and

X₁ is unsubstituted or phenyl-substituted C₁-C₈alkyl.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/09046

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D209/24 C07D405/06 C07D319/06 C07F5/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 739 073 A (KATHAWALA FAIZULLA G) 19 April 1988 (1988-04-19) cited in the application column 8, line 39 -column 16, line 46 ---	1-17
Y	SLISKOVIC D R ET AL: "INHIBITORS OF CHOLESTEROL BIOSYNTHESIS. 2. 1,3,5-TRISUBSTITUTED 2-(TETRAHYDRO-4-HYDROXY-2-OXOPYRAN-6-YL)ET HYLPYRAZOLES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 1, January 1990 (1990-01), pages 31-38, XP000974226 ISSN: 0022-2623 * Schema II * page 34, left-hand column --- -/--	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

27 November 2002

Date of mailing of the international search report

05/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seymour, L

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/09046

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MIYACHI, NOBUHIDE ET AL: "A novel synthetic method of HMG-CoA reductase inhibitor Nk-104 via a hydroboration-cross coupling sequence" TETRAHEDRON LETT. (1993), 34(51), 8267-70, XP001027579 the whole document ---	1-17
Y	ISHIKURA M ET AL: "Investigation of the Reaction of N-Substituted Indolylborates: Palladium Catalyzed Cross-Coupling Reactions and Intramolecular Alkyl Migration Reactions" JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 36, no. 4, 1999, pages 873-880, XP001026833 HETEROCORPORATION. PROVO., US ISSN: 0022-152X * Schema 1 * table 1 ---	1-17
A	WO 98 45265 A (MARCUCCHIO SEBASTIAN MARIO ;RODOPOULOS MARY (AU); WEINGOLD HELMUT ()) 15 October 1998 (1998-10-15) page 5, line 23 -page 6, line 10; claims 5,12,16,22,23 ---	1-14
Y	page 5, line 23 -page 6, line 10; claims 5,12,16,22,23 ---	15-17
A	WO 99 47474 A (TINKL MICHAEL ;HAFNER ANDREAS (CH); CIBA SC HOLDING AG (CH)) 23 September 1999 (1999-09-23) claim 1 -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/09046

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4739073	A	19-04-1988	US 5354772 A	11-10-1994
			AT 31718 T	15-01-1988
			AU 570021 B2	03-03-1988
			AU 2261283 A	18-06-1984
			CA 1210405 A1	26-08-1986
			CY 1579 A	20-12-1991
			DE 3375137 D1	11-02-1988
			DK 97890 A , B,	19-04-1990
			DK 359284 A	20-07-1984
			WO 8402131 A1	07-06-1984
			EP 0114027 A1	25-07-1984
			FI 842615 A , B,	28-06-1984
			GR 79042 A1	02-10-1984
			HK 11191 A	13-02-1991
			HU 35642 A2	29-07-1985
			IE 56262 B1	05-06-1991
			IL 70286 A	31-08-1987
			JP 1752942 C	23-04-1993
			JP 3047167 A	28-02-1991
			JP 4040343 B	02-07-1992
			LU 88670 A9	29-04-1996
			NZ 206338 A	31-08-1987
WO 9845265	A	15-10-1998	AU 716306 B2	24-02-2000
			AU 6813498 A	30-10-1998
			WO 9845265 A1	15-10-1998
			CN 1255123 T	31-05-2000
			EP 0986541 A1	22-03-2000
			JP 2002505663 T	19-02-2002
			NZ 337951 A	28-02-2000
			US 2002032339 A1	14-03-2002
WO 9947474	A	23-09-1999	AU 3144299 A	11-10-1999
			CA 2321791 A1	23-09-1999
			WO 9947474 A1	23-09-1999
			EP 1064243 A1	03-01-2001
			JP 2002506836 T	05-03-2002
			US 6417357 B1	09-07-2002